Akoya (AKYA) Misses Q4 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
Akoya Reports Fourth Quarter and Full Year 2021 Operating Results and Provides 2022 Financial Outlook
March 14, 2022 4:05 PM EDTQ4 2021 revenue $16.2 million and FY 2021 revenue $54.9 million
FY 2022 revenue guidance $69 - 71 million
MARLBOROUGH, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (Akoya), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2021.
Our strong finish to 2021 demonstrates the continued and accelerating adoption of our leading spatial biology solutions and is a result of sound execution of our financial and strategic plans, said Brian McKelligon, Chief Executive Officer, Akoya Biosciences. We set another record in quarterly revenue, grew our installed base to nearly 700... More
